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clinics of a regional hospital in southern Taiwan. Outpatients with type 2 diabetes
were invited to participate the interviews for measuring QoL. After finishing the
TTO exercise for measuring QoL, a semi-structured interview was followed to ex-
plore participant’s view on themethods and specific attributes for trading off. TTO
results were transformed to utility value, and interviews were recorded, tran-
scribed verbatim and analyzed by constant comparison approach to saturation.
RESULTS:Of all, 96 of the 100 participants completed the TTO (mean age: 55.811.0
years, 54.2% male) the average utility is 0.6920.217, yet most participants (n68,
70.8%) accepted current health status and life expectancy and were reluctant to
give up any life years to exchange a full health. At interviews, participants revealed
their worries, anxiety, discomfort and disturbances of daily life related to diabetes,
but those factors were not considered when trading life year and health status
during TTO exercise; instead, satisfaction of life expectancy, child-caring and self-
recognition on values of life were considered. Information provided by healthcare
providers, peer supports and religions were found to help patients cope with the
disease and improve health-related QoL. CONCLUSIONS: For patients with
chronic, stable diabetes, an adaptation process may have diluted the impacts of
patients’ concerns on health-related QoL, and hence trading on life years and
health status is inappropriate to measure QoL utility. Further study is to explore
feasibility of TTO at different stages of diabetic complications, and cross-validate
between TTO and other utility measures.
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OBJECTIVES: Quality-of-life (QoL) is increasingly recognized as an important out-
comemeasure that provides information on the burden of diabetes on the physical,
mental and social aspects of patients’ health. To pick up disease-related changes in
QoL of diabetes patients in Korea, we administered Korean Audit of Diabetes-
Dependent Quality-of-Life (KR-ADDQoL) instrument. METHODS: A prospective,
observational study was carried out on type 2 diabetic patients from the diabetic
clinics of 24medical centers throughout Korea. A total of 413 diabetic patients aged
40 years and over were assessed for Health-Related QoL (HRQoL). HRQoL was as-
sessedwith KR-ADDQoL instrument. RESULTS: Patients with diabetes were 589.7
years old (47.2% female), had diabetes for 7.06.2 years. Themean present QoLwas
0.40.97 (range: 3 [extremely bad] to 3 [excellent]) and diabetes-dependent QoL
was 1.50.98 (range: 3 [very much better] to 1 [worse]). Patients with diabetes
and those with hypertension reported lower present QoL, compared with diabetes
only (0.31.01, 0.60.85; p0.0161). The mean KR-ADDQoL average weighted im-
pact (AWI) score was 2.41.8. Patients with 15-20 years of diabetes reported sig-
nificantly worse AWI scores (3.71.6) compared with those with 10-15 years
(1.91.5). A negative impact of diabetes was seen in all the dimensions of KR-
ADDQoL. Freedom to eat and people’s reaction remained as the most (mean AWI
scores: 4.32.8) and least (1.32.1) affected QoL domains, respectively, when
weighting was considered. CONCLUSIONS: Type 2 diabetes has a negative impact
in HRQoL in the patients studied. The findings highlighted the impact of diabetes
on QoL with particular reference to the effects on freedom to eat, and freedom to
drink. Our study contributed to the knowledge of QoL in Korean patients with type
2 diabetes by using a diabetes-specific QoL instrument. These findings suggest that
the impact of diabetes in QoL among Asian is similar [ADDQoL AWI score in Sin-
gaporeans: 2.61.9].
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OBJECTIVES: We assessed medication beliefs and evaluated association between
race andmedication beliefs among low-incomeAfricanAmericans andCaucasians
with diabetes. METHODS: A cross-sectional self-administered written survey of
Type 2 diabetes patients was conducted at a primary-care clinic affiliated with a
hospital serving an urban population. Inclusion criteria were being 18 years or
older, diagnosed with Type 2 diabetes at least 6 months prior to the time of the
survey, and taking oral anti-diabetic medication. Exclusion criteria were use of
insulin or inability to read and write in English. The survey included the Beliefs
about Medications Questionnaire to assess individuals’ medication beliefs. Analy-
sis of variance was used to compare differences in medication beliefs across race.
RESULTS: Usable responses were obtained from 236 of 397 individuals who satis-
fied inclusion and exclusion criteria, for a response rate of 59%. The sample was
53% African American, 47% Caucasian, 63% female and 72% had annual household
income of less than $25,000. A majority (63%) had at most completed high school
education. Mean belief scores for necessity of taking diabetes medications were
higher for Caucasians (3.74) than for African Americans (3.49) (p0.0396) after ad-
justing for age, gender, education, time since diabetes diagnosis, number of med-
ications taken for diabetes and total medications taken for all conditions. Mean
scores for perceived harm from medications were higher for African Americans
(2.55) than Caucasians (2.29) (p0.0162). Mean scores for perceived overuse ofmed-
icines by prescribers were higher for African Americans (3.32) as compared to Cau-
casians (3.04) (p0.0497). CONCLUSIONS: Small differences in medication beliefs
between African Americans and Caucasians were observed after adjusting for
other covariates. Exploration of the role of medication beliefs in racial disparities
may be informative.
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OBJECTIVES: Individuals with diabetes type 2 usually show low compliance with
secondary prevention measures. Economic theory states that, from the demand
side, insurance reduces the incentives for individuals to claim self-protection and
hence, increases the ex-ante moral hazard while in the other hand, it selects indi-
viduals with lower risk preferences. This analysis aims to determine the net effect
of contributory and subsidized insurance on preventive effort in individuals un-
dergoing diabetes in Colombia. METHODS: Using data from the National Health
Survey-2007,we selected individuals aged between 18-69 andpreviously diagnosed
with diabetes (n  1446). We performed an instrumental variables model by treat-
ing the choice of insurance as endogenous and using self-employment and the
proportion of individuals insured under either contributory and subsidized regi-
mens in the municipality as instruments. In this analysis we present marginal
effects. RESULTS: We found evidence that, controlling for all covariates, health
insurance increases prevention care in individuals under the Contributory regimen
(0.259; SE 0,126) in comparison to uninsured individuals; however, for those en-
rolled in the Subsidized regimen the results were not significantly different when
comparing to uninsured individuals(0.047; SE 0.113). CONCLUSIONS: The internal-
ization of costs by health insurers throughout the life of individuals suffering from
diabetes is essential to improve secondary prevention in diabetes in the country. In
this case, we found that, unlike the Subsidized Regimen, the more comprehensive
benefits plan in the Contributory scheme is likely to increase the cost faced by the
insurer, encouraging it to promote preventive activities among individuals with
diabetes. This finding has important policy implications given the rapid growth in
health care costs to treat diabetes in Colombia. These results are easily inferred for
other preventable chronic conditions such as chronic obstructive pulmonary dis-
ease, heart disease and hypertension.
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OBJECTIVES: To review the variety of diabetes risk assessment tools and their
validity METHODS: An electronic literature search of the EMBASE, MEDLINE,
Cochrane library was undertaken using key words ‘diabetes risk’ and screening
or assessment or score or questionnaire, ‘diabetes prediction’, ‘medical screen-
ing’, and ‘health risk assessment’ from 1995-2010. References of identified arti-
cles were also manually searched. RESULTS: The electronic search retrieved a
total of 2168 articles reporting diabetes risk questionnaires. Deletion of duplicates
by Endnote andmanual culling produced a list of 41 questionnaires developed in 22
countries, with the majority (n26) developed in North America and Europe; the
remainder were from Asia (n10), Middle-East (n3), Africa (n1) and Austra-
lia(n1). Of the 41 questionnaires, 17 were developed for screening of undiagnosed
diabetes and 24 for predicting the risk of developing disease in the next 2-20 years.
All identified tools are short questionnaires of 2-16 questions with common vari-
ables of diabetes risk factor such as age, gender, waist circumference, BMI, family
history of diabetes, history of hypertension or antihypertensive medications being
used for risk assessment.While scoring format and cutoff points are diverse across
the questionnaires, the overall sensitivity, specificity, area under receiver operat-
ing characteristic curve (ROC) ranged from 40-97% and 24-86% and 62-87% respec-
tively. Comparatively speaking, there weremore tools developed for predicting the
risk of developing disease in recent years. CONCLUSIONS: There is a trend of
increasing availability of diabetes prediction tools with the existing diabetes risk
assessment tools being generally short questionnaire aiming for ease of use in
clinical practice. The overall performance of existing tools showed moderate to
high accuracy in their predictive performance. However, there are not enough
reports about their application in real-life clinical settings to allow an assessment
of their effectiveness in routine practice.
PDB53
PRESCRIBING PATTERN OF ANTIDIABETIC DRUGS IN T2DM PATIENTS
TERTIARY CARE HOSPITAL IN INDIA
Raval AD1, Dhanaraj E2, Bhansali A3
1Institute of Pharmacy Nirma University, Ahemdabad, India, 2National Institute of
Pharmaceutical Education and Research, Mohali, Punjab, India, 3Post Graduate Institute of
Medical Education and Research, Chandigarh, India
OBJECTIVES: To identify patterns of antidiabetic drug prescribing in established
type 2 diabetes mellitus, to assess compliance of prescribing patterns with current
evidences and to describe determinants of the choice of antidiabetic drugs.
METHODS: Patients with established T2DM who attended the endocrinology Out-
patient Clinic in Postgraduate Institute of Medical Education and Research, Chan-
digarh, India were evaluated in a retrospective observational manner. Patients
were examined for social, demographical and clinical variables and medications.
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RESULTS: A total of 1185 established T2DM patients were assessed. Themean (SD)
age was 55 (10) years andmean duration of diabetes (SD) of 10 (7) years. Metformin
was themost commonly prescribed drug [827 (70%)], in general followed by insulin
[627 (53%)], sulfonylureas [520 (44%)], and pioglitazone [329 (28%)]. A total of 348
(29%) patients receivedmonotherapy and 837 (71%) received combination therapy.
The most frequently prescribed monotherapy was insulin [214 (62%)], followed by
metformin in 81 (23%), sulfonylurea in 49 (14%) and pioglitazone in 4 (1%) patients.
Family history(OR 1.76, 95%CI 1.18, 2.64), diabetes duration (OR 2.62, 95% CI 2.05,
3.36), HbA1c (OR 1.25, 95%CI 1.01, 1.50), neuropathy(OR 1.57, 95% CI, 1.14, 2.2), ne-
phropathy(OR 1.77, 95% CI 1.40, 2.24), retinopathy (OR 1.97, 95% CI 1.63, 2.40), Cor-
onary Artery Disease (CAD) (OR 1.57, 95% CI, 1.14, 2.2) and diabetic foot t (OR 1.62,
95% CI 1.12, 2.40) were all significantly associated with the insulin therapy. Obese
and overweight patients were prescribed oral antidiabetic drugs. [metformin (OR
1.25, 95% CI 1.15, 1.35), sulfonylurea (OR 1.28, 95% CI 1.01, 1.61)]. CONCLUSIONS:
This study finding indicates that medication use was consistent with evidence
based practice guidelines in T2DM. There was, however, scope for improvement in
prescribing, especially in the T2DM patients with complications.
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OBJECTIVES: There is a growing interest in the use of electronic medical records
(EMRs) for clinical research. The study describes a collaborative research project
that uses an EMR database to explore the level of diabetic care in patients with type
2 diabetes in a primary care setting. METHODS: A retrospective study was con-
ducted using the GE Centricity electronic medical records (EMR) database of a pri-
mary care physicians group. Patients with type 2 diabetes were identified using
ICD-9 codes of 250.xx (January 1, 2004 toMarch 31, 2009). Patients 18 years of age,
with two or more visits with their respective physicians, and having an active
status in the database were selected. Demographic characteristics, clinical param-
eters (HbA1c, LDL, HDL)medication use, and number of office visitswere identified.
Data was extracted using Microsoft SQL and descriptive statistical analyses were
conducted using SPSS version 18.0. RESULTS: The study identified 4,598 patients
(mean age: 67 12.9 years and males: 51.8%) with type 2 diabetes. A total of 24,590
office visits were recorded with a mean of 14.1 visits and 127 days between visits.
3,100 (61.3%) patients had HbA1c levels  7; 1,473 (29.1%) patients had levels be-
tween 7-9; and 484 (9.6%) patients had levels  9. 3,970 (59.2%) patients had LDL
below 100 mg/dL and 2,737 (40.8%) had LDL greater than 100 mg/dL. Mean number
of active medications were 2.34 and diabetes medications were 1.94. Combination
drugs were used the most compared with amino acid derivatives and amylin
analogs. CONCLUSIONS: The collaborative research project has been established
between clinicians and researchers, a baseline data extraction has been developed
and now further studywill be necessary to prove that specific interventions in high
risk patients, i.e. HbA1c  9, can ultimately improve care.
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OBJECTIVES: A central Texas health plan implemented a pharmacist-led diabetes
medication management program (MMP) offering co-pay waivers for diabetes re-
lated medications and supplies. Medication adherence, diabetic control and
healthcare costs were compared between patients enrolled in the MMP and
matched control patients.METHODS: Patientswere enrolled in theMMP if they had
baseline A1C levels  7.5% and three years of continuous enrollment throughout
the study period (“rolling” enrollment from 7/06-12/08). The enrollees and controls
were matched 1:1 by age, gender, baseline A1C, and Charlson comorbidity index
(CCI). A1C and adherence (Medication Possession Ratio (MPR)) were measured one
year before and two years after implementation. A difference in difference analysis
used paired t-tests to compare changes in MPR and A1C. Healthcare costs were
analyzed by year, group, types of service, diabetes-related and all-cause claims.
RESULTS: 144 patientswere enrolled in theMMP for at least two years. AverageA1C
decreased by 0.8 in controls and 1.5 inMMPpatients; the difference between groups
was statistically significant (P0.01). While both groups declined in MPR for oral
antidiabetic drugs (MMP:10% vs. Control:19%), the difference between the groups
was statistically significant (P0.009). After two years, the average permember per
month (PMPM) costs increased by 16% and 36% inMMP and control groups, respec-
tively. The increasewasmainly attributable to growth in diabetes-related drug and
outpatient claims in the MMP group. Inpatient costs appeared to be the greatest
difference between the two groups, decreasing by 38% in the MMP group and in-
creasing by 159% in the control group.CONCLUSIONS:When compared tomatched
control patients, the MMP showed improved patient clinical and adherence mea-
sures. Although two-year PMPM costs increased, the significant difference in inpa-
tient costs indicates a potential for longterm savings.
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OBJECTIVES: Assess the clinical and economic impact of pharmacist education,
monitoring, andmanagement of patients with diabetes mellitus (DM) enrolled in a
free clinic that serves a rural indigent population.METHODS:Data from77 patients
continuously enrolled in a newly established pharmacist service were analyzed.
Patients were18 years of age, qualified for free care on the basis of income and/or
insurance status, and had a diagnosis of DM upon entry. Under a collaborative
agreement, pharmacists educated patients on DM, counseled patients on lifestyle
modifications, assessed appropriateness of drug therapy, and managed drug ther-
apy for DM and associated comorbid conditions. Clinical impact was measured by
changes from baseline in hemoglobin A1c (A1c) levels, blood pressure, and lipid
levels over a 12 month period. Using cost estimates published in the literature,
economic impact was calculated based upon expected savings per 1% decrease in
A1c levels. RESULTS: Mean A1c levels were 10.6% at baseline (SD 2.5 %). At one
year, A1c levels decreased an average of 2.3% (P0.001), and 44.2% of patients had
an A1c 7%. A significant number of patients achieved A1c goal by one year
(P0.0001). Significant decreases in mean values were also noted for systolic blood
pressure (SBP) (P0.02), LDL-cholesterol (P 0.001), and triglycerides (P 0.001). A
significant number of patients reached a SBP goal 130 mmHg (P0.033), LDL-
cholesterol 100 mg/dL (P0.0001), or triglycerides 150 mg/dL (P0.0001). Based
on an expected savings of $1,118 per 1% decrease in HbA1C levels, the average
savings per patient was $2,600, for a total savings potential of $167,364.
CONCLUSIONS: Pharmacist management of patients with DM has the potential to
significantly impact clinical outcomes and improve costs of care for patients in
underserved rural areas.
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OBJECTIVES:Average adherence to therapy in patients with diabetes is only 67.5%.
This study aims to evaluate the impact of a pharmacist-based diabetes manage-
ment program on improving medication adherence among diabetic patients.
METHODS: Data collected during a collaborative program in which trained phar-
macists provided diabetes management including medication, education and diet
and lifestyle modification counseling to diabetic patients was obtained. Medica-
tions dispensed before (in 2007) and during (in 2008) the intervention was recorded
for the patients receiving the intervention and controls (matched on age 5 years,
HbA1C0.1%, gender, and baseline cholesterol levels) as part of this retrospective,
longitudinal study. Patientswith two ormore visits at the participating pharmacies
were included in the study. Medication Possession Ratios (MPRs) were calculated
for every patient. Analysis involving descriptive statistics and t-tests were per-
formed using SAS version 9.2. RESULTS: A total of 135 cases and 243 controls were
included in the study of which 53.3% (n72) and 50.78% (n122) were females,
respectively. The mean age (SD) of cases and controls was similar 48.6 (11.4) and
47.4 (13.1) years, respectively. The mean MPR(SD) of cases improved from 3.41(3.7)
in 2007 to 5.12(10.7) in 2008 (p0.0902). The MPR(SD) for controls, reduced from
2.96(2.9) in 2007 to 2.16(6.8) in 2008. When the changes in MPR(SD) of every individ-
ual were compared cases showed greater change of 1.75(1.4) on an average as
compared to 0.015(1.8) for controls(p0.0907). Although not significant (p0.083),
the percentage of cases that were non-adherent reduced by around 50% from 8.9%
in 2007 to 4.4% in 2008. CONCLUSIONS: Adherence to medication in diabetic pa-
tients may be improved thorough a planned pharmacists-based disease manage-
ment program. Further, longitudinal data may be needed to conclusively indicate
the impact of pharmacists based intervention.
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OBJECTIVES: We assessed the impact of the use of a generic substitute of rosigli-
tazone (an anti-diabetic drug) on patient outcomes and treatment costs.
METHODS: From the Maccabi Healthcare Services computerized databases we
identified three groups of diabetic patients: 1. Patients who purchased the branded
medication Avandia® and switched entirely to its’ generic substitute Rossini®
(same number of packages and dosage; the intervention group; N1,632), 2. Pa-
tients who switched to Rossini® partially (different number of packages and/or
different dosage; the control group; N440), and 3. Patients who did not switch to
Rossini® at all (N897). For each patient we retrospectively obtained and compared
the following parameters 6-months prior to, and 6-months following the switch:
HbA1c levels, number of medication packages purchased, number of physician
visits, hospital and emergency room admissions, and pharmaceutical costs.
RESULTS: In patients who switched entirely from Avandia® to Rossini® we found a
45% decrease in treatment costs (p0.001), as compared with a 29% decrease in
costs in the control group that continued treatment with Avandia® (p0.001) and
37% decrease (p0.001) in the control group that partially switched to Rossini® (in
the control groups there was a decline in the number of packages that were pur-
chased after the switch). In the intervention group, we observed a reduction of 0.1%
in HbA1c levels [from 7.61.3% to 7.51.4% (p0.001)] in comparison to a non-
significant difference in the two other groups [from 7.91.5% to 7.91.6% (p0.198)
and from 7.81.4% to 7.71.7% (p0.261), respectively].We found a decrease in the
number of physician visits, and no difference in the number of hospitalization days
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